BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 30097523)

  • 1. Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study.
    Ly KI; Oakley DH; Pine AB; Frosch MP; Chiou SH; Betensky RA; Pomerantz SR; Hochberg FH; Batchelor TT; Cahill DP; Dietrich J
    Oncologist; 2019 Mar; 24(3):402-413. PubMed ID: 30097523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gliomatosis Cerebri Among Children and Adolescents: An Individual-Patient Data Meta-analysis of 182 Patients.
    Georgakis MK; Tsivgoulis G; Pourtsidis A; Petridou ET
    J Child Neurol; 2019 Jun; 34(7):394-401. PubMed ID: 30887873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas.
    Broniscer A; Chamdine O; Hwang S; Lin T; Pounds S; Onar-Thomas A; Shurtleff S; Allen S; Gajjar A; Northcott P; Orr BA
    Acta Neuropathol; 2016 Feb; 131(2):299-307. PubMed ID: 26744350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gliomatosis cerebri: no evidence for a separate brain tumor entity.
    Herrlinger U; Jones DTW; Glas M; Hattingen E; Gramatzki D; Stuplich M; Felsberg J; Bähr O; Gielen GH; Simon M; Wiewrodt D; Schabet M; Hovestadt V; Capper D; Steinbach JP; von Deimling A; Lichter P; Pfister SM; Weller M; Reifenberger G
    Acta Neuropathol; 2016 Feb; 131(2):309-319. PubMed ID: 26493382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases.
    Kwon MJ; Kang SY; Cho H; Lee JI; Kim ST; Suh YL
    Brain Pathol; 2020 Mar; 30(2):235-245. PubMed ID: 31435963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gliomatosis cerebri: clinical characteristics, management, and outcomes.
    Chen S; Tanaka S; Giannini C; Morris J; Yan ES; Buckner J; Lachance DH; Parney IF
    J Neurooncol; 2013 Apr; 112(2):267-75. PubMed ID: 23341100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series.
    Anghileri E; Schettino C; Pollo B; Farinotti M; Silvani A; Paterra R; Patanè M; DiMeco F; Bruzzone MG; Eoli M; Cuccarini V
    Neurol Sci; 2020 Aug; 41(8):2111-2120. PubMed ID: 32114667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis.
    Georgakis MK; Tsivgoulis G; Spinos D; Liaskas A; Herrlinger U; Petridou ET
    World Neurosurg; 2018 Dec; 120():e818-e854. PubMed ID: 30172970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, neuroimaging and histopathological features of gliomatosis cerebri: a systematic review based on synthesis of published individual patient data.
    Georgakis MK; Tsivgoulis G; Spinos D; Dimitriou NG; Kyritsis AP; Herrlinger U; Petridou ET
    J Neurooncol; 2018 Nov; 140(2):467-475. PubMed ID: 30117023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas.
    Divé I; Steidl E; Wagner M; Filipski K; Burger MC; Franz K; Harter PN; Bähr O; Fokas E; Herrlinger U; Steinbach JP
    Oncology; 2021; 99(4):215-224. PubMed ID: 33472203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and survival of gliomatosis cerebri: a population-based cancer registration study.
    Georgakis MK; Spinos D; Pourtsidis A; Psyrri A; Panourias IG; Sgouros S; Petridou ET
    J Neurooncol; 2018 Jun; 138(2):341-349. PubMed ID: 29464663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types.
    Park S; Suh YL; Nam DH; Kim ST
    Clin Neuropathol; 2009; 28(2):73-82. PubMed ID: 19353837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revisiting prognostic factors of gliomatosis cerebri in adult-type diffuse gliomas.
    Shin I; Sim Y; Choi SH; Park YW; Lee N; Ahn SS; Chang JH; Kim SH; Lee SK
    J Neurooncol; 2024 May; ():. PubMed ID: 38700610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
    Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C
    Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri.
    Narasimhaiah D; Miquel C; Verhamme E; Desclée P; Cosnard G; Godfraind C
    Neuropathology; 2012 Feb; 32(1):30-7. PubMed ID: 21481010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of presentation and failure in patients with gliomatosis cerebri treated with partial-brain radiation therapy.
    Kandula S; Saindane AM; Prabhu RS; Hanasoge S; Patel KR; Shu HK; Curran WJ; Crocker IR
    Cancer; 2014 Sep; 120(17):2713-20. PubMed ID: 24845411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gliomatosis cerebri having a poor performance status without recurrence after radiotherapy: a single institutional experience.
    Jung TY; Yoon MS; Kim YH; Jung S; Kim IY; Jang WY; Moon KS; Lee KH; Kim SK
    Clin Neurol Neurosurg; 2015 Mar; 130():1-5. PubMed ID: 25569296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary gliomatosis cerebri involving gray matter in pediatrics: a distinct entity? A multicenter study of 14 cases.
    Chappé C; Riffaud L; Tréguier C; Carsin-Nicol B; Veillard D; Chiforeanu DC; Grill J; Frappaz D; André N; Millot F; Vinchon M; Sirvent N; Edan C
    Childs Nerv Syst; 2013 Apr; 29(4):565-71. PubMed ID: 23306961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma.
    Galanaud D; Chinot O; Nicoli F; Confort-Gouny S; Le Fur Y; Barrie-Attarian M; Ranjeva JP; Fuentès S; Viout P; Figarella-Branger D; Cozzone PJ
    J Neurosurg; 2003 Feb; 98(2):269-76. PubMed ID: 12593610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri.
    Kwon MJ; Kim ST; Kwon MJ; Kong DS; Lee D; Park S; Kang SY; Song JY; Nam DH; Kato Y; Choi YL; Suh YL
    Brain Pathol; 2012 May; 22(3):307-17. PubMed ID: 21929658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.